Navigation Links
Study Weighs Cost, Benefit of Gene Tests Before Warfarin Rx
Date:1/20/2009

The screens resulted in better patient outcomes but at high price, researchers say

TUESDAY, Jan. 20 (HealthDay News) -- Genetic testing isn't cost-effective in guiding initial dosing of the blood thinner warfarin in patients with atrial fibrillation (a type of abnormal heart rhythm), a University of Cincinnati study finds.

Warfarin is used to prevent blood clotting in these patients. In 2007, the U.S. Food and Drug Administration changed the labeling for warfarin to suggest that doctors consider genetic testing before using the blood thinner.

"There are certain genes that are known to contribute to an increased sensitivity to warfarin," study lead investigator Dr. Mark Eckman, professor of medicine, explained in a UC news release.

"The idea behind genetic testing -- also known as pharmacogenetic-guided dosing -- is to help guide the initial, and possibly lower, dose of warfarin for patients," Eckman said. "The hope is that more accurate dosing will translate into decreased major bleeds during the initiation phase of warfarin dosing, which is the first month or so."

He and his colleagues analyzed the findings of three published studies and then created a model to estimate the cost-effectiveness of genetic testing.

They found that genotype-guided dosing did result in better patient outcomes but at a cost of more than $170,000 per quality-adjusted life year gained. They also found that there is only a 10 percent chance that genotype-guided dosing is likely to be cost-effective. The findings were published in the Jan. 20 issue of the journal Annals of Internal Medicine.

The researchers concluded that genotype-guiding dosing is cost effective if it:

  • is used for patients at high risk for hemorrhage;
  • prevents more than 32 percent of major bleeding events;
  • is available within 24 hours;
  • costs less than $200.

"This could be accomplished if testing were done in-house, at lower cost and without delays," said Eckman. Currently, most of these tests have to be sent to outside laboratories, which can lead to increased cost and treatment delays.

More information

The U.S. Agency for Healthcare Research and Quality has more about warfarin.



-- Robert Preidt



SOURCE: University of Cincinnati, news release, Jan. 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study compares 2 nonsurgical treatments for reflux disease
2. Study examines racial disparities in survival among patients diagnosed with lung cancer
3. Study shows rise in antibiotic resistant pediatric head and neck infections
4. Study: Growth in research comes at a steep price
5. National Childrens Study Begins Recruiting
6. A Study In This Months Journal Of Nervous And Mental Disease Reveals Hope For Recovery From Suicidal Thinking And Treatment Resistant Mental Illness
7. Tufts receives NIH grant to study obesity prevention in new immigrants
8. New Research From EBRI: Study Examines Issues in Capping Tax Exclusion of Health Coverage
9. 2009 Most Wired Survey and Benchmarking Study Opens Today
10. Seattle Reproductive Medicine Study Investigates Newly Formulated Medications for Luteal Support in IVF
11. Newer Antipsychotics Pose Cardiac Risk: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Weighs Cost, Benefit of Gene Tests Before  Warfarin Rx
(Date:5/24/2016)... ... 24, 2016 , ... The number of health insurance policies ... over last year, according to data in the forthcoming AIS’s Directory of Health ... with a slight decrease in risk-based groups and a slight increase in administrative-services-only/self-funded ...
(Date:5/24/2016)... ... May 24, 2016 , ... Bio-Logic Aqua® Research Water Life ... and a trainer for Ageless Grace ( http://www.agelessgrace.com ) to discuss healthier lifestyles, ... 16, 2016. , Formerly a Northwestern University Literature Professor, Kinst gravitated to her ...
(Date:5/24/2016)... ... ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene Day on May 28 and ... who do not have access to a toilet, even when they’re on their periods. , ... The (sometimes hilarious) results help shine a light on the awkwardness that women face while ...
(Date:5/24/2016)... ... May 24, 2016 , ... In light of recent ... of the potential of contaminated well water throughout the Houston area. , Heavy floodwaters ... well water that’s exposed to contaminants. Residents may not even be aware of the ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... today announced a licensing relationship that will deliver a new series of Q&A ... will put the medical knowledge and expertise of Harvard Medical School faculty into ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
(Date:5/24/2016)... KONG , May 24, 2016 /PRNewswire/ ... COMBO ™ , la première ... des cathéters destinés à l,intervention portant sur ... (FAV)   OrbusNeich, entreprise mondiale ... permettant de changer la vie, a élargi ...
Breaking Medicine Technology: